Get the Stockscreener App
154.38
0.08%
-0.13
After Hours:
154.66
0.28
+0.18%
Belite Bio Inc Adr stock is traded at $154.38, with a volume of 87,935.
It is down -0.08% in the last 24 hours and down -9.11% over the past month.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
See More
Previous Close:
$154.51
Open:
$157.1
24h Volume:
87,935
Relative Volume:
0.53
Market Cap:
$6.17B
Revenue:
-
Net Income/Loss:
$-77.61M
P/E Ratio:
-67.18
EPS:
-2.2979
Net Cash Flow:
-
1W Performance:
-2.74%
1M Performance:
-9.11%
6M Performance:
+37.32%
1Y Performance:
+147.01%
1-Day Range:
$153.48
$158.95
1-Week Range:
$153.48
$160.24
52-Week Range:
$56.10
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
154.38 | 6.18B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Initiated | BofA Securities | Buy |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-02-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-20-25 | Initiated | Mizuho | Neutral |
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
View All
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares - Investing.com
Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS - Stock Titan
Belite Bio CSO Nathan Mata sells $155,777 in shares By Investing.com - Investing.com South Africa
Belite Bio (BLTE) CSO pre-planned sale of 1,000 ADS around $160 - Stock Titan
Belite Bio (BLTE) CSO sells 1,000 ADS in planned trades - Stock Titan
Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1 - Yahoo Finance
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus - Barchart
Belite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares - MarketBeat
(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under 10b5-1 plan - Stock Titan
Belite bio CSO Nathan Mata sells $159,162 in shares - Investing.com
Belite bio CSO Nathan Mata sells $159,162 in shares By Investing.com - Investing.com India
Belite Bio (BLTE) CSO sells 1,000 ADS in planned open-market trades - Stock Titan
A Look At Belite Bio (BLTE) Valuation As Tinlarebant NDA Submission Progresses - Sahm
Belite Bio (NASDAQ:BLTE) Insider Sells $162,640.00 in Stock - MarketBeat
Belite Bio chief scientific officer Nathan Mata sells $162,641 in shares - Investing.com India
Belite Bio chief scientific officer Nathan Mata sells $162,641 in shares By Investing.com - Investing.com South Africa
Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan - Stock Titan
Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor ConferenceSlideshow - Seeking Alpha
Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference - MarketBeat
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, Apr-28-2026 09 - marketscreener.com
Belite Bio (NASDAQ:BLTE) Insider Sells $159,560.00 in Stock - MarketBeat
Belite Bio chief scientific officer Nathan Mata sells $159,555 in stock - Investing.com India
Belite Bio (BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan - Stock Titan
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit - The Manila Times
Belite Bio CSO Nathan Mata sells $166,283 in shares By Investing.com - Investing.com Australia
Belite Bio CSO Nathan Mata sells $166,283 in shares - Investing.com
Belite Bio (BLTE) CSO sells 1,000 ADS in Rule 10b5-1 trades - Stock Titan
Belite Bio CSO Nathan Mata sells $170,384 in shares By Investing.com - Investing.com South Africa
Belite Bio CSO Nathan Mata sells $170,384 in shares - Investing.com
BELITE BIO (BLTE) CEO gains 10,000 shares from vested RSUs - Stock Titan
[Form 4] BELITE BIO, INC Insider Trading Activity - Stock Titan
Belite Bio (BLTE) CFO RSUs vest into 10,000 ordinary shares - Stock Titan
Belite Bio to Participate in Four Upcoming Investor Conferences - markets.businessinsider.com
Four Belite Bio conference appearances are set from April 28 to May 26 - Stock Titan
Belite Bio chief scientific officer sells $166,000 in shares By Investing.com - Investing.com Canada
Belite Bio chief scientific officer sells $166,000 in shares - Investing.com
Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS disclosed - Stock Titan
Buy Initiation on Tinlarebant Developer: First-Mover Stargardt Opportunity Drives DCF-Based $200 Target Amid Key Late-Stage Catalysts and Risks - TipRanks
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th - marketscreener.com
Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - MarketBeat
Belite Bio begins rolling NDA submission for Stargardt treatment By Investing.com - Investing.com India
Belite Bio CSO Nathan Mata sells $163,594 in shares By Investing.com - Investing.com Canada
Belite Bio CSO Nathan Mata sells $163,594 in shares - Investing.com
Belite Bio begins rolling NDA submission for Stargardt treatment - Investing.com
Belite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease - TipRanks
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):